MeritValue

NYMOX PHARMACEUTICAL CORP

NYMXFdata completeness 63%10 fiscal years on file

Data notes: no data for concept 'totalDebt'; no data for concept 'epsDiluted'; no data for concept 'interestExpense'

The thesis, from the filings

NYMOX PHARMACEUTICAL CORP earns about -547% on equity, but has diluted owners by 21% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2020FY 2021FY 2022FY 2023FY 2024
Revenue$5,0001$02$03$03—
Net income−$11.7M4−$12.5M5−$6.58M6−$8.84M6−$4.49M6
Operating cash flow−$10M7−$9.82M8−$5.21M9−$4.06M9−$2.6M9
Capital expenditure$13,00010$6,00011$012$3,00012$012
Free cash flow (derived)−$10.1M7−$9.83M8−$5.21M9−$4.06M9−$2.6M9
Total debt—————
Cash & equivalents$3.61M13$830,00013———
Diluted shares78.0M85.5M90.5M93.5M94.5M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.72
your share of equity
Profit it earned you last year
−$0.48
Free cash flow it threw off
−$0.28
Debt you’d be carrying
—

10 shares is a claim on −$0.72 of net worth that earned you −$0.48 and generated −$0.28 of cash last year.

iii. Is this a good business?
Moat signal · return on equity
-547% avg · 5y
FY20 -547%FY21 —FY22 —FY23 —FY24 —

It earned an average -547% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
+21% shares · 5y

Share count is up 21% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 20-F · period ending 2020-12-31 · accession 0001640334-23-000736 (Revenue)
  2. 20-F · period ending 2021-12-31 · accession 0001640334-24-001383 (Revenue)
  3. 20-F · period ending 2022-12-31 · accession 0001640334-25-000972 (Revenue)
  4. 20-F · period ending 2020-12-31 · accession 0001640334-23-000736 (ProfitLossAttributableToOwnersOfParent)
  5. 20-F · period ending 2021-12-31 · accession 0001640334-24-001383 (ProfitLossAttributableToOwnersOfParent)
  6. 20-F · period ending 2022-12-31 · accession 0001640334-25-000972 (ProfitLossAttributableToOwnersOfParent)
  7. 20-F · period ending 2020-12-31 · accession 0001640334-23-000736 (CashFlowsFromUsedInOperatingActivities)
  8. 20-F · period ending 2021-12-31 · accession 0001640334-24-001383 (CashFlowsFromUsedInOperatingActivities)
  9. 20-F · period ending 2022-12-31 · accession 0001640334-25-000972 (CashFlowsFromUsedInOperatingActivities)
  10. 20-F · period ending 2020-12-31 · accession 0001640334-21-000680 (PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities)
  11. 20-F · period ending 2021-12-31 · accession 0001640334-24-001383 (PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities)
  12. 20-F · period ending 2022-12-31 · accession 0001640334-25-000972 (PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities)
  13. 20-F · period ending 2020-12-31 · accession 0001640334-22-000622 (CashAndCashEquivalents)